HIV Prevention Drug Faces Distribution Hurdle in 2026

A revolutionary HIV prevention drug that requires just two injections per year is reaching millions, even as humanitarian groups navigate access challenges.

Lenacapavir made headlines after studies showed it offers virtually complete protection from HIV infection. The twice-yearly treatment represents a massive improvement over daily pills, making prevention far easier for people at risk.

Gilead Sciences, the drug's manufacturer, struck a deal in late 2024 with The Global Fund to Fight AIDS, Tuberculosis and Malaria. That partnership is now distributing lenacapavir to 2 million people across low and middle-income countries where HIV rates remain highest.

Doctors Without Borders recently asked Gilead for direct access to purchase limited supplies of the medication. After months of discussions, the company declined, directing the organization to continue obtaining the drug through The Global Fund partnership instead.

The organization called the decision "unconscionable" and criticized the approach to distribution. They currently receive lenacapavir through the existing Global Fund channels for their HIV prevention programs.

The Ripple Effect

Despite the access debate, lenacapavir's reach continues expanding. The Global Fund partnership represents one of the largest commitments to HIV prevention in recent years, targeting the populations who need it most.

The twice-yearly injection format solves a critical problem in HIV prevention. Daily pills require consistent access to healthcare and perfect adherence, barriers that have limited prevention efforts in under-resourced areas.

This new form of preexposure prophylaxis, known as PrEP, works by blocking the virus from establishing infection. Six months of protection from a single doctor's visit means fewer missed doses and better outcomes.

Public health experts view long-acting prevention as a game changer for controlling HIV spread. The 2 million person commitment through The Global Fund puts this technology in the hands of communities facing the highest infection rates.

Multiple pathways for drug distribution often emerge as new treatments scale globally, with manufacturers, governments, and humanitarian groups all playing roles in reaching patients.

The conversation around lenacapavir access shows both the promise of medical innovation and the ongoing work to ensure breakthroughs reach everyone who needs them.